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Background: The chronic nature of inflammatory bowel disease leads to considerable impairment on the health
related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the
Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in
patients with IBD for the first time in China, as compared with other therapies of different levels. Furthermore, the impact
of different medical therapies on marriage, employment and economic burden in IBD patients were also evaluated.
Methods: Consecutive patients who met inclusion/exclusion criteria were investigated with MCIBDQ, SF-36, disease
activity index (DAI), marriage, employment and economic burden questionnaires before and after treatment.
Results: MCIBDQ showed significant reliability and validity both in CD and UC patients. The scores of total SF-36, total
MCIBDQ and all domains were found significantly increased, while both DAI and health transition on general health
scores were found significantly decreased after infliximab treatment (all P < 0.001). Scores of SF-36 and MCIBDQ
increased significantly more in infliximab group than non-infliximab group (all P < 0.05). Infliximab treatment was
suggested to significantly reduce the negative impact on love (P = 0.037), increase work time (P = 0.016) and ease
economic burden (P = 0.048).
Conclusions: MCIBDQ was demonstrated to be a reliable and valid scale applied in Chinese IBD patients.
Infliximab treatment was found to significantly improve HRQOL in IBD patients in comparison with conventional
treatments. Negative impact on marriage, employment, and economic status was found in patients with IBD.
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InfliximabBackground
Inflammatory bowel disease (IBD) is an immune-mediated,
chronic disorder characterized by remittent or progressive
inflammation that may affect the entire gastrointestinal
tract, with two major clinical forms: Crohn’s disease (CD)
and ulcerative colitis (UC) [1]. The natural history of the
lesions in the alimentary tract, together with the complica-
tions, frequent physician visits, associated hospitalizations,
and even the adverse events of medical therapy or surgery,
lead to considerable impairment on the health related
quality of life (HRQOL) in patients with IBD [2]. Recent* Correspondence: shenjun_med@yeah.net; ranzhihua62@sina.cn
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unless otherwise stated.studies have indicated that patients with active disease
suffered poorer HRQOL than patients with quiescent
disease [3,4]. Thus, the effective goals of treatment were
not only relieving symptoms, diminishing disease activity,
or delaying progression, but also improving the patients’
quality of life [5]. Therefore, improvement of patient’s
HRQOL became one of the fundamental goals of IBD
treatment [6].
Infliximab (IFX) is a genetically engineered monoclonal
tumor necrosis factor-alpha (TNF-α) antibody that repre-
sents the first effective biologic therapy, which greatly
improves the treatment options in managing IBD [7]. It
has already been reported that infliximab had a consider-
able efficacy on induction and maintenance of remission
in refractory patients with CD and UC [8,9]. Recent stud-
ies on the impact of infliximab on HRQOL in patients
with IBD found that anti-TNF therapy was effective onThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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showed controversial effects on patients’ HRQOL [12].
However, these findings were not widely accepted.
When studies evaluating HRQOL were performed,
Inflammatory Bowel Disease Questionnaire (IBDQ) was
widely applied for HRQOL assessment in patients with
IBD, and was proven to be valid and reliable [13]. IBDQ
was translated into different languages and validated for
each adaption [14,15]. In eastern countries, the incidence
of IBD used to be much lower than that of Western
countries, but experienced a significant increase in
recent decades, making IBD no longer an uncommon
disease [16]. However, studies concerning the effect of
infliximab treatment on IBD patients’ HRQOL have not
been reported in China to date.
The present study aimed to validate the Chinese version
of IBDQ, evaluate and compare the impact of infliximab
therapy and other different therapies on HRQOL in
patients. Furthermore, the impact of infliximab therapy
on marriage, employment, and economic burden in IBD
patients were also evaluated.
Methods
Patients
A total of 119 consecutive patients with IBD (84 with
CD and 35 with UC) hospitalized at Renji hospital from
Jan 2011 to June 2012 were enrolled in this study. Each
of them fulfilled the inclusion criteria, which included:
definite diagnosis of CD or UC according to the “World
Gastroenterology Organization Practice Guidelines for
the Diagnosis and Management of IBD in 2010” [17]; the
ability to comprehend and complete the self-administered
questionnaire with or without assistance. The exclusion
criteria were the presence of a psychiatric disorder, stoma,
malignancy, any condition that apparently affect the qual-
ity of life, or refusal to be recruited in this study. This
protocol was approved by Research Ethics Committee
of Shanghai Jiao-Tong University, School of Medicine,
and written informed consent was obtained from all the
participants before inclusion.
Tools of assessment
IBDQ, SF-36 and general health status
IBDQ was originally developed by Irvine as a physician-
administered disease-specific questionnaire regarding the
IBD patient’s status in the previous 2 weeks before admin-
istration [13]. Thereafter, the self-administered IBDQ was
developed and validated by Irvine and colleagues [18],
then Mainland Version of IBDQ (MCIBDQ) was trans-
lated and validated by Zhou [15]. In the present study,
MCIBDQ was applied. It consisted of 32 questions divided
into four domains: bowel symptoms (10 items), systemic
symptoms (5 items), emotional function (12 items) and
social function (5 items). Every question had gradedresponses and was scored on a 7-point Likert scale from 1
(worst situation) to 7 (best situation), reflecting the QOL
of the subjects in the previous 2 weeks. For validation,
HRQOL was also assessed using a widely accepted generic
instrument assessing 8 dimensions in life - 36-Item Short
Form Health Survey Scale (SF-36) [19], and Chinese
version was adapted in this study [20,21]. The details of
MCIBDQ and the Chinese version of SF-36 were listed on
Additional file 1: Table S1, with higher scores indicating
better health status. In SF-36, the single item scale on
health transition was scored separately as self-evaluation
on the changing of general health status, with lower scores
indicating better status.
Disease activity indices
Avoiding invasive procedures, Harvey–Bradshaw simple
index (HBI) [22] was calculated in patients with CD, and
Walmsley simple colitis activity index (CAI) [23] was
used in patients with UC. These two simplified indices
relied entirely on symptoms, and highly correlated with
the previous complex indices, making evaluation of dis-
ease activity and therapeutic response much easier.
Thus, these two indices were widely utilized. In both
indices, <4 were indicated as remissions or quiescent
and ≧4 were considered as active status.
Marriage, employment and economic burden
Marriage, employment and economic status are three
major impaired aspects after being diagnosed with IBD
among patients. Thus, a special scale consisting of six
items on general status of marriage, employment and
economic burden was developed and used in this study.
Scores were calculated by every single item, and each
item reflected a certain aspect in life. An additional file
showed the content of the scale of marriage, employ-
ment and economic burden [see Additional file 2].
Validation of MCIBDQ
In general, the validation mainly included reliability and
validity. The reliability of an instrument can be considered
as the degree of consistency of its measurement [24], with
two main forms: test-retest reliability and internal
consistency. For a medical or health care instrument to
be clinically useful, it must possess validity. Validity, the
ability of an instrument to assess fully what it was
intended to measure, was assessed in 4 ways according
to standard definitions including content validity,
construct validity, discriminant validity, and criterion
validity [25]. Although Leong et al. [26] translated and
validated the IBDQ in Hong Kong in 2003 and Zhou
YX et al. [15] finished the version in Mainland Chinese in
2007, differences in geographic regions, economy, lifestyle,
population source, and sample representation suggested
that re-validation of MCIBDQ is needed in the present
Table 1 General information
Items CD UC IBD
Number 74 30 104
Gender: male/female 54/20 17/13 71/33
Mean age(years ± SD) 30.73 ± 10.38 34.97 ± 11.77 31.95 ± 10.91
Disease duration:≤
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tion in Mainland China, lifestyle and health concept
saw significant alteration in the patients residing, in-
creasing the necessity for the re-validation of MCIBDQ.
Details about the background and process were shown
on Additional file 3.
Study design and statistical analysis
The data collected from the consecutive patients who
met all inclusion/exclusion criteria were results of a
stratified-controlled and matched prospective cohort
study, which was designed to determine the reliability
and validity of MCIBDQ, and the impact of infliximab
treatment on HRQOL in patients with IBD, as compared
with other therapies of different levels. The question-
naires were self-administered in most of the cases. A
gastrointestinal physician, who was blinded to the results
of MCIBDQ, SF-36 and additional questions (marriage,
employment and economic burden), would then interview
the subjects upon completion to address any questions or
issues completing the questionnaires. This physician then
scored the disease activity respectively for CD and UC
patients on the basis of HBI and CAI. Only a few indi-
viduals were unable to read but could comprehend the
questions, and completed the questionnaires with the
physician’s help. To measure the daily function and
quality of life respectively at the time of diagnosis and
2 weeks after the treatment, participants were asked to
complete the same questionnaires twice at an interval
of 2 weeks to 2 months. All the scales were scored as
recommended by their original inventor.
According to highest therapeutic level the subjects had
ever received, the participants who completed the ques-
tionnaires twice were stratified into four treatment
groups as following: 1)anti-inflammatory drugs (oral or
intravenous); 2) glucocorticoids (oral, intravenous or
local application); 3) immunosuppressive agents (oral or
intravenous); 4) biological agents (intravenous IFX) [27].
According to the times of infliximab infusions (dosage:
5 mg/kg; infusion intervals: administered at weeks 0, 2,
and 6, and then every 8 weeks), group 4 could also be
stratified into 2 subgroups: a) <4 times; b) ≥4 times. The
effect of different therapies on HRQOL among these
four treatment groups was determined and compared on
the basis of the “variation of scores” (defined as the latter
scores minus the former scores) [28,29].
Furthermore, participants who completed the ques-
tionnaires twice were divided into two paired groups
(infliximab group and control group) according to IBD
subtype, disease activity, disease duration, gender, age,
career, literacy and marriage, with every subject matched
his/her paired subject. Thus, the impact of different
therapies on HRQOL between the paired groups was
also assessed. Moreover, general status of marriage,employment and economic burden was described in this
study.
Cronbach’s α was determined by all available data ex-
cluding missing responses, while criterion validity and
discriminant validity were determined by all available
data including missing responses, which could be re-
placed according to the original inventors’ suggestion
[30]. Construct validity were determined using the data
of fully-completed MCIBDQ results.Results
Demographics and general information
A total of 119 consecutive subjects finished the ques-
tionnaires for the first time, and 104 of them completed
the questionnaires a second time. The general information
of subjects who finished both before and after infliximab
infusion was shown on Table 1.Validation of MCIBDQ
Reliability
Internal consistency Internal consistency could be rep-
resented by Cronbach’s α (values of >0.7 indicating
adequate consistency). Cronbach’s α of the 4 MCIBDQ
domains ranged from 0.88– 0.95 in CD and from 0.86–
0.94 in UC, and the total Cronbach’s α for MCIBDQ was
0.98 in CD and 0.97 in UC, suggesting that MCIBDQ
had a strong internal consistency (Table 2).Validity
Content validity Kaiser-Meyer-Olkin (KMO) Measure
of Sampling Adequacy and Bartlett’s Test of Sphericity
showed that MCIBDQ possess a significant construct val-
idity in both CD patients (KMO value = 0.938, P < 0.001)
and UC patients (KMO value = 0.837, P < 0.001), suggest-
ing the appropriateness of MCIBDQ for factor analysis.
Table 2 Details and validation of MCIBDQ
Domain
Cronbach’s α Discriminant ability
CD UC CD UC





Na Mean (95% CI) Na Mean(95% CI) Na Mean (95% CI) Na Mean (95% CI)
Bowel symptoms 149 0.92 43 0.93 84 58.96(56.88-61.05) 71 44.52(41.72-47.33) <0.001 32 56.11(51.70-60.52) 33 38.70(34.74-42.67) <0.001
Systemic symptoms 155 0.88 65 0.86 85 25.08(23.82-26.35) 71 17.94(16.39-19.50) <0.001 32 23.63(21.37-25.89) 33 18.00(15.85-20.15) <0.001
Emotional function 154 0.95 60 0.94 85 66.63(63.91-69.35) 71 50.20(46.67-53.73) <0.001 32 60.10(54.34-65.86) 33 45.59(41.30-49.89) <0.001
Social function 131 0.88 58 0.89 84 27.46(25.96-28.97) 70 20.26(18.44-22.07) <0.001 32 26.44(23.64-29.24) 33 17.82(15.33-20.31) <0.001
Total 121 0.98 52 0.97 83 177.83(170.83-184.84) 70 133.52(124.43-142.41) <0.001 32 166.28(152.01-180.55) 33 120.11(108.30-131.93) <0.001


















Figure 1 Scree plots of MCIBDQ from the exploratory factor analysis. The horizontal line represents the cut-off for selecting the number of
factors. A, CD patients group; B, UC patients group.
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that 4 principal components (each eigenvalue >1) provided
71.04% cumulative contribution of variance, indicating that
4 aggregating dimensions might conveniently summarize
the questionnaire, as shown by the scree plot in Figure 1A.
Similar to CD patients, it was suggested that 4–5 principal
components (each eigenvalue >1) provided 70.58-74.19%
cumulative contribution of variance, as shown by the scree
plot in Figure 1B. The four designed aggregating dimen-
sions were identified as the explorative factor analysis
demonstrated.
Discriminant validity Independent t-test showed sig-
nificantly higher total MCIBDQ and dimensional scores in
“remission” group than “active” group in both CD and UC
groups (all P < 0.001, Table 2), suggesting that MCIBDQ
discriminated well between groups of CD and UC patients
either in remission or with active disease.Table 3 Pearson correlation coefficients between MCIBDQ do
SF-36
dimensions









PF .621 .666 .681 .740
RP .607 .648 .692 .712
BP .724 .750 .741 .776
GH .666 .710 .715 .618
VT .724 .790 .832 .740
SF .634 .670 .726 .746
RE .563 .594 .686 .570
MH .664 .680 .781 .650
Pearson correlation coefficients in bold were those expected to be moderate or hig
All correlations were significant at the 0.001 level (2-tailed).Criterion validity Moderate to high correlations (r ranged
from 0.568–0.832) between MCIBDQ domains and SF-36
dimensions were found in this study, which was a perfect
fit with the expectation of their correlations. (Table 2)
Pearson correlations between “total MCIBDQ score and
all domain scores” and total SF-36 score were significant,
positive and significant (all P < 0.001), with coefficients
ranging from 0.790 to 0.895 in patients with CD and
from 0.747to 0.856 in patients with UC. Similarly, “total
MCIBDQ score and all domain scores” for both CD
(r ranged from −0.552 to −0.646) and UC (r ranged
from −0.473 to −0.686) correlated negatively and sig-
nificantly (all P < 0.001) with disease activity indices.
Furthermore, significant correlations were also indicated
between “total MCIBDQ score and all domain scores”
and health transition on general health in both CD (all
P < 0.001, r ranged from 0.526 to 0.596) and UC (r ranged
from 0.476 to 0.531). No particular low correlationmains and SF-36 dimensions











.701 .659 .653 .701
.704 .668 .728 .728
.673 .675 .652 .615
.499 .568 .608 .579
.588 .737 .708 .653
.602 .650 .689 .653
.581 .638 .729 .628
.502 .566 .670 .494
h.
Table 4 Pearson correlation coefficients between total
MCIBDQ score and 4 domain scores and SF-36 total score,
disease activity index and self-evaluation on general
health score
Total SF-36 score DAIa Health transition
MCIBDQ domains in CD
Bowel symptoms .790 -.646 -.527
Systemic symptoms .846 -.580 -.596
Emotional function .887 -.576 -.576
Social function .826 -.552 -.526
Total MCIBDQ score .895 -.617 -.586
MCIBDQ domains in UC
Bowel symptoms .747 -.686 -.507
Systemic symptoms .810 -.473 -.519
Emotional function .856 -.498 -.476
Social function .780 -.580 -.524
Total MCIBDQ score .847 -.604 -.531
aDisease activity index according to HBI or CAI.
All correlations were significant at the 0.001 level (2-tailed).
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(Tables 3 and 4)
The impact of different therapies on HRQOL
Before and after infliximab treatment
In total, 41 participants (36 for CD and 5 for UC) with
infliximab infusions completed the questionnaires before
and after infliximab infusions. It was found that after
infliximab treatment, DAI significantly decreased, total
MCIBDQ score and all domain scores significantlyFigure 2 The scores (including 95% CI) before and after infliximab treat
C, Systemic symptoms score; D, Emotional function score; E, Social function scoincreased, total SF-36 score significantly increased, and
score of health transition on general health signifi-
cantly decreased in patients with IBD (Figure 2 and see
Additional file 4: Table S2]).
The times of infliximab infusion
The comparison between the subgroups (a: 17 patients;
b: 24 patients) showed that, the decrease of score of health
transition on general health was significantly greater in
group b versus group a. Moreover, compared with group
a, there were trends that DAI decreased more and bowel
symptoms domain score of MCIBDQ increased more in
group b although it failed to reach statistical significance
(see Additional file 4: Table S2).
Comparisons among different therapies
Compared with patients treated without infliximab (N = 63,
38 for CD and 25 for UC), the improvements of overall SF-
36 scores, overall MCIBDQ score and most domain scores
were significantly greater in infliximab group than those of
the conventional treatment group. We found similar results
in comparison between group 3 and group 4 (Figure 3 and
see Additional file 4: Table S2.
Comparisons between paired groups
Similar to the results above, paired comparison suggested
overall SF-36 scores, overall MCIBDQ score and all
domain scores increased more significantly in infliximab
group than in placebo group. Furthermore, compared
with control group, the score of health transition on gen-
eral health decreased more in infliximab group. However,ment. A, Disease activity index score; B, Bowel symptoms score;
re; F, Total MCIBDQ score; G, Total SF-36 score; H, Health transition score.
Figure 3 Score variations (including 95% CI) of non-IFX treatment group and IFX treatment group. A, Variation of disease activity index
score; B, Variation of bowel symptoms score; C, Variation of systemic symptoms score; D, Variation of emotional function score; E, Variation of
social function score; F, Variation of total MCIBDQ score; G, Variation of total SF-36 score; H, Variation of health transition score.
Xu et al. BMC Gastroenterology 2014, 14:199 Page 7 of 10
http://www.biomedcentral.com/1471-230X/14/199it only showed a trend without significance (Figure 4 and
see Additional file 4: Table S2).
Marriage, employment and economic burden
According to the results, infliximab treatment significantly
reduced the negative impact on marriage (P = 0.037),
increased work time (P = 0.016) and eased economic
burden (P = 0.048) in IBD patients. Comparisons among
different therapies showed work time increased significantlyFigure 4 Paired comparison between non-IFX treatment group and IF
activity index score; B, Variation of bowel symptoms score; C, Variation of s
E, Variation of social function score; F, Variation of total MCIBDQ score; G, Vmore in IFX group (P = 0.039). Furthermore, paired
comparison suggested negative impact on love in IFX
group reduced significantly more (P = 0.050). Detailed
results were shown on Additional file 5: Table S3.
Discussion
The measurement of HRQOL is not only an important
approach in the clinical evaluation, but also in the thera-
peutic management of individual patients [31]. Thus, aX treatment group (including 95% CI). A, Variation of disease
ystemic symptoms score; D, Variation of emotional function score;
ariation of total SF-36 score; H, Variation of health transition score.
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in urgent need currently. In the present study, MCIBDQ
was demonstrated reliable and valid, with strong and
significant correlation to SF-36 and DAI, and with
moderate correlation to transition on general health.
These results were similar both in CD and in UC patients,
in line with the results of other language versions.
HRQOL including several domains can be impaired in
many ways in IBD patients. In pace with the shifting of
health concepts, patients consider the quality of life after
being diagnosed and treated more, rather than barely
dealing with the symptoms. Infliximab, as a safe and
effective biological agent, was mainly used in patients
with refractory CD and UC. The present study suggested
that infliximab treatment significantly alleviate disease
activity and improve HRQOL of IBD patients, in accord-
ance with similar preceding studies [10,11]. Moreover,
compared to patients without infliximab infusion and pa-
tients treated with immunosuppressor, HRQOL increased
significantly more in patients with infliximab infusion.
Probably due to the insufficient sample size of group 1
and 2, their comparisons to infliximab group did not show
significant difference. To our knowledge, this was the first
time the impact of different treatments on HRQOL was
explored in China.
It was noteworthy that the improvement of DAI did
not show significant difference between groups, which
may be associated with the fact that DAI before treatment
in infliximab group was not much greater than control
group, but lower. As known, IFX is a huge economic
burden for ordinary Chinese IBD patients. Since IFX treat-
ment is not reimbursed in Mainland China, its administra-
tion is largely limited to relatively rich patients. On the
other hand, regardless of DAI, the rich tend to have better
healthcare and therapeutic effect after infliximab infusion,
making DAI even lower in infliximab group and improve
no greater than the control group, which is quite different
from studies of other countries [7,10].
Many life aspects, such as marriage, employment and
economic burden, can affect the quality of life in IBD
patients. In this study, the social and cultural back-
ground might be the explanations. This study initially
described the impact on “marriage, employment and eco-
nomic burden” and assessed their changes after different
treatments. Negative impact on marriage, employment
and economic status was found in IBD patients.
After being diagnosed with IBD, many patients experi-
enced a sense of inferiority, feeling embarrassed for the
symptoms they suffered and receiving less understanding
with regard to their social interactions and performance
[32]. Moreover, long duration of awful experience brought
them fatigue and heavy economic burdens, which placed a
substantial impact on their marriage. Regarding employ-
ment, 32.97% lost their jobs because of the disease, whichseemed to disagree with the working information of these
subjects. The urgency of defecation or even incontinence
is one prominent problem for IBD patients, compelling
them to leave their original working environment where
access to toilets was inconvenient [32]. Actually, high
work pressure usually resulted in relapse for IBD patients,
making their work time inevitably less. It was shown that
infliximab treatment might help to reduce the negative
impact on love and increase their work time, which was
estimated to perform better than conventional therapies.
Interestingly, it was found that infliximab administration
helped lighten the economic burden of IBD patients. In
China, infliximab is not included in the Essential Medicine
List (EML), neither covered by healthcare insurance
provided by the government. As a result, only patients
with high incomes would choose infliximab treatment,
and they may not be as sensitive as low-income patients
regarding medical cost, while they tend to pay more atten-
tion to efficacy. If it turns out to be effective, they are
more inclined to be satisfied with the therapy and the cost.
Maybe this partly explains the reduction of economic
burden in patients who received infliximab infusions.
Conclusion
MCIBDQ was demonstrated to be a reliable and valid
scale applied in Chinese IBD patients. Infliximab treatment
was found to significantly alleviate disease activity and to
significantly improve HRQOL of IBD patients. Moreover,
compared with patients without infliximab infusion, inflixi-
mab significantly increased HRQOL. Negative impact on
marriage, employment and economic status was found
in IBD patients. It was shown in the present study that
infliximab treatment might help to reduce the negative
impact on love, increase their work time and lighten
their economic burden.
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different treatment groups.
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employment and economy among different treatment groups.
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